A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

Completed · Phase 4

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of this study is to assess the impact of belimumab on immune response to pneumococcal vaccine in subjects with Systemic Lupus Erythematosus (SLE).

Key facts

Study ID

NCT01597492

Run by

Human Genome Sciences Inc., a GSK Company

People needed

79

Starts

2012-05-31

Expected to finish

2015-09-24

Last updated by the study team

2018-08-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• GSK Investigational Site — Birmingham, Alabama, United States
• GSK Investigational Site — Paradise Valley, Arizona, United States
• GSK Investigational Site — Shreveport, Louisiana, United States
• GSK Investigational Site — Baltimore, Maryland, United States
• GSK Investigational Site — Cumberland, Maryland, United States
• GSK Investigational Site — Hagerstown, Maryland, United States
• GSK Investigational Site — New York, New York, United States
• GSK Investigational Site — Toledo, Ohio, United States
• GSK Investigational Site — Duncansville, Pennsylvania, United States
• GSK Investigational Site — Austin, Texas, United States
• GSK Investigational Site — Austin, Texas, United States
• GSK Investigational Site — Houston, Texas, United States
• GSK Investigational Site — Burlington, Vermont, United States
• GSK Investigational Site — Seattle, Washington, United States
• GSK Investigational Site — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.